Retatrutide · source year
16 selected, source-linked Retatrutide records carrying a 2026 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
16 selected records.
3 represented types.
16 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06383390 at 2026-09-09T19:17:17.103Z. Its registry update date was 2026-08-24, and PeptideScanner's reviewed identity mapping was retatrutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05929066 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was retatrutide.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42567543 at 2026-08-10T10:49:13.603Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-08-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 38323122 at 2026-08-10T10:49:06.879Z. PubMed recorded a metadata revision date of 2026-07-31 and an Entrez history date of 2024-02-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05882045 at 2026-08-10T18:10:03.944Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05929079 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-30, and PeptideScanner's reviewed identity mapping was retatrutide.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42527705 at 2026-08-10T18:13:57.053Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42493254 at 2026-08-10T18:13:56.730Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
ClinicalTrials.gov lists an active, not recruiting Retatrutide study sponsored by Eli Lilly and Company.
Source: ClinicalTrials.gov ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42425580 at 2026-08-10T18:13:55.212Z. PubMed recorded a metadata revision date of 2026-07-09 and an Entrez history date of 2026-07-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 42264536 at 2026-07-30T16:14:18.135Z. PubMed recorded a metadata revision date of 2026-06-09 and an Entrez history date of 2026-06-09. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 41056349 at 2026-07-30T16:20:41.592Z. PubMed recorded a metadata revision date of 2026-05-22 and an Entrez history date of 2025-10-07. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Regulatory
FDA issued a warning letter to Gram Peptides that describes the agency's findings about products marketed with retatrutide and tirzepatide.
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 37178114 at 2026-07-30T16:23:33.798Z. PubMed recorded a metadata revision date of 2026-03-27 and an Entrez history date of 2023-05-13. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 40735804 at 2026-07-30T16:23:38.757Z. PubMed recorded a metadata revision date of 2026-03-07 and an Entrez history date of 2025-07-30. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 39868848 at 2026-07-30T16:31:18.163Z. PubMed recorded a metadata revision date of 2026-01-27 and an Entrez history date of 2025-01-27. PeptideScanner associated this retained record with the identity slug retatrutide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗